TABLE 2.
Antibiotics used in combination with polymyxins in patients receiving NVCT and VCT
| Antibiotic used in combination with polymyxinsa | NVCT group (n = 203) |
VCT group (n = 30) |
||
|---|---|---|---|---|
| No. (%) of patients | No. (%) of patients with infection-related mortality | No. (%) of patients | No. (%) of patients with infection-related mortality | |
| Carbapenemsb | 124 (61.1) | 37 (29.8) | 20 (66.7) | 4 (20.0) |
| Fluoroquinolonesc | 52 (25.6) | 16 (30.8) | 7 (23.3) | 1 (14.3) |
| Beta-lactam–beta-lactamase inhibitord | 51 (25.1) | 8 (15.7) | 1 (3.3) | 0 (0.0) |
| Aminoglycosidese | 14 (6.9) | 4 (28.6) | 6 (20.0) | 1 (16.7) |
| Cephalosporinsf | 37 (18.3) | 6 (16.2) | 0 (0.0) | |
| Aztreonam | 13 (6.4) | 2 (15.4) | 4 (13.3) | 0 (0.0) |
| Rifampin | 28 (13.8) | 11 (39.3) | 4 (13.3) | 1 (25.0) |
| Tigecycline | 46 (22.7) | 12 (26.1) | 1 (3.3) | 0 (0.0) |
a
Each patient could receive more than 1 type of polymyxin combination throughout the treatment course.
b
The carbapenems used included meropenem, ertapenem, doripenem, and imipenem-cilastin.
c
The fluoroquinolones used included levofloxacin and ciprofloxacin.
d
The beta-lactam–beta-lactamase inhibitors used included piperacillin-tazobactam, ampicillin-sulbactam, and amoxicillin-clavulanate.
e
The aminoglycosides used included amikacin and gentamicin.
f
The cephalosporins used included ceftazidime, ceftriaxone, and cefepime.